Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the sale, the chief operating officer now directly owns 329,977 shares in the company, valued at approximately $7,236,395.61. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anish Patel also recently made the following trade(s):

• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.18, for a total value of $524,706.00.

Enliven Therapeutics Trading Down 0.6 %

Shares of NASDAQ ELVN opened at $21.41 on Wednesday. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -11.27 and a beta of 1.03. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The stock’s 50-day moving average is $22.72 and its 200 day moving average is $24.20.

Wall Street Analyst Weigh In

Several research firms have weighed in on ELVN. Robert W. Baird raised their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $38.25.

Hedge Funds Weigh In On Enliven Therapeutics

A number of large investors have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after buying an additional 601,611 shares in the last quarter. Vanguard Group Inc. increased its stake in Enliven Therapeutics by 2.9% in the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock worth $44,452,000 after purchasing an additional 55,283 shares during the period. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock worth $26,611,000 after purchasing an additional 313,019 shares during the period. Geode Capital Management LLC increased its stake in Enliven Therapeutics by 9.9% in the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock worth $19,164,000 after purchasing an additional 67,813 shares during the period. Finally, State Street Corp increased its stake in Enliven Therapeutics by 2.9% in the 3rd quarter. State Street Corp now owns 745,944 shares of the company’s stock worth $19,051,000 after purchasing an additional 21,018 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.